Why the study?
Pulmonary hypertension patients with acute respiratory failure face high morbidity and mortality, but the optimal respiratory support strategy across different grades of right ventricular dysfunction severity was unknown.
Does high-flow nasal cannula therapy compared to noninvasive ventilation improve 28-day mortality and intubation rates in pulmonary hypertension patients with acute respiratory failure?
Does high-flow nasal cannula therapy compared to noninvasive ventilation improve 28-day mortality and intubation rates in pulmonary hypertension patients with acute respiratory failure?
In pulmonary hypertension patients with acute respiratory failure, noninvasive ventilation is preferable to high-flow nasal cannula for those with severe right ventricular dysfunction due to lower intubation rates, while both are equally effective for mild to moderate dysfunction.
Answers are grounded in this paper and cite their sources.
HFNC associated with higher intubation in severe RV dysfunction; leaves open optimal support strategy in pulmonary hypertension.
Pulmonary hypertension (PH) patients with acute respiratory failure (ARF) face high morbidity and mortality rates. This study aimed to determine the optimal respiratory support strategy (high-flow nasal cannula [HFNC] vs noninvasive ventilation) across different grades of RV dysfunction severity in these patients. In this retrospective cohort study, we stratified 90 PH patients with ARF into mild, moderate or severe right ventricular (RV) dysfunction subgroups via propensity score matching. We compared 28-day mortality rates and intubation rates as primary outcomes between the HFNC and noninvasive ventilation (NIV) groups. There were no differences in 28-day mortality between HFNC therapy and NIV among the RV dysfunction subgroups. In patients with severe RV dysfunction, however, HFNC therapy was associated with significantly greater intubation rates. Both therapies improved right heart function, but NIV yielded better oxygenation. HFNC therapy is as effective as NIV in mild to moderate RV dysfunction; nevertheless, NIV might be more advantageous for severe cases. These findings can help in choosing between HFNC therapy and NIV for PH patients who present with ARF. Nonetheless, larger prospective trials are needed to validate these findings.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: